Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
2024

Using Semaglutide and Liraglutide to Help with Alcohol Problems

Sample size: 227866 publication Evidence: high

Author Information

Author(s): Lähteenvuo Markku MD PhD, Tiihonen Jari MD PhD, Solismaa Anssi MD PhD, Tanskanen Antti PhD, Mittendorfer-Rutz Ellenor PhD, Taipale Heidi PhD

Primary Institution: University of Eastern Finland

Hypothesis

Are glucagon-like peptide-1 receptor (GLP-1) agonists effective in the treatment of alcohol use disorder?

Conclusion

The use of semaglutide and liraglutide is associated with a significantly lower risk of hospitalization due to alcohol use disorder.

Supporting Evidence

  • Individuals using semaglutide had a 36% lower risk of hospitalization due to alcohol use disorder.
  • Liraglutide users had a 28% lower risk of hospitalization due to alcohol use disorder.
  • The study followed participants for a median of 8.8 years.

Takeaway

This study found that two medications, semaglutide and liraglutide, can help people who have problems with alcohol by reducing their chances of needing to go to the hospital.

Methodology

This cohort study used nationwide registry data from Sweden to analyze hospitalization risks for individuals with alcohol use disorder during periods of GLP-1 agonist use versus nonuse.

Potential Biases

The study's design may introduce biases related to confounding factors.

Limitations

As an observational study, it can only establish associations, not causality.

Participant Demographics

The cohort included 63.5% male and 36.5% female individuals, with a mean age of 40.0 years.

Statistical Information

P-Value

0.64 for semaglutide, 0.72 for liraglutide

Confidence Interval

95% CI, 0.50-0.83 for semaglutide; 95% CI, 0.57-0.92 for liraglutide

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1001/jamapsychiatry.2024.3599

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication